Showing results (91-100 of 141) with videos related to

Sort By:
Pageof 15
Cytometry. Part a : the Journal of the International Society for Analytical Cytology|December 25, 2002
Assessment of tumor cell repopulation after chemotherapy for advanced ovarian cancer: pilot studyA J Davis, W Chapman, D W Hedley, et al.
International Journal of Cancer|January 17, 1995
Reduction of tumour intracellular pH and enhancement of melphalan cytotoxicity by the ionophore NigericinP J Wood, J M Sansom, K Newell, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 20, 2008
Survival and PSA response of patients in the TAX 327 study who crossed over to receive docetaxel after mitoxantrone or vice versaD R Berthold, G R Pond, R de Wit, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 19, 2015
Statistical controversies in clinical research: end points other than overall survival are vital for regulatory approval of anticancer agentsE D Saad, M Buyse
Revista Do Hospital Das Clinicas|January 1, 1996
[Evidence-based medicine]E D Saad, H Grunspun
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 20, 2008
Progression-free survival and time to progression as primary end points in advanced breast cancer: often used, sometimes loosely definedE D Saad, A Katz
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 12, 2014
Delivery of perioperative chemotherapy for bladder cancer in routine clinical practiceC M Booth, D R Siemens, Y Peng, et al.
British Journal of Cancer|January 1, 1993
pH dependent cytotoxicity of N-dodecylimidazole: a compound that acquires detergent properties under acidic conditionsM J Boyer, I Horn, R A Firestone, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 27, 2012
Comparison of absolute benefits of anticancer therapies determined by snapshot and area methodsB Seruga, G R Pond, P C Hertz, et al.
Oral Oncology|August 9, 2002
A Phase II trial of docetaxel and cisplatin in patients with recurrent or metastatic nasopharyngeal carcinomaJ S McCarthy, I F Tannock, P Degendorfer, et al.
Pageof 15